RE: Long Covid 19 trail16 Mar 2022 10:29
Key Highlights:
· Clinical Study underway with partners Swiss PharmaCan AG and Glow LifeTech Ltd to determine the influence of MGC Pharma's proprietary supplement ArtemiC Support® in patients with Long COVID syndrome.
· The Clinical Study received Ethics Committee approval from Spanish research foundation, IDIAP Jordi Gol, on 9 December 2021.
· The Clinical Study will enrol 150 patients suffering from post-acute COVID syndrome (Long COVID syndrome) with 50 patients already enrolled, and is expected to be completed in February 2022.
· Patients will take ArtemiC Support® for 6 weeks under supervision of their doctor, with their progress measured against a Post-COVID Functional Scale (PCFS), and a 10-point Likert scale, one, two, three and six weeks after treatment commences.
· This is a pilot study to initially obtain partial results on the effectiveness and safety of ArtemiC Support® in improving the functional status and symptomatology in patients suffering from Long COVID Syndrome.
· A further randomised, double-blind, placebo-controlled study, to get full information on efficacy and safety of the food supplement in patients suffering from Long-COVID is expected to follow, dependent on the results of the initial pilot study.